Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

Conclusions The cardiovascular benefits and safety profile of finerenone in participants with stage 4 CKD were consistent with the overall FIDELITY population; this was also the case for albuminuria and the rate of eGFR decline. The effects on the composite kidney outcome were not consistent over time.PMID:36927680 | DOI:10.2215/CJN.0000000000000149

Source: Clinical Journal of the American Society of Nephrology : CJASN - March 17, 2023 Category: Urology & Nephrology Authors: Pantelis Sarafidis Rajiv Agarwal Bertram Pitt Christoph Wanner Gerasimos Filippatos John Boletis Katherine R Tuttle Luis M Ruilope Peter Rossing Robert Toto Stefan D Anker Zhi-Hong Liu Amer Joseph Christiane Ahlers Meike Brinker Robert Lawatscheck George Source Type: research